Spero Cataland

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Thomas Barbour, Marie Scully, Gema Ariceta et al. · Kidney International Reports · 2021 · 66 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +17

Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data

Ioannis Tomazos, Anthony J. Hatswell, Spero Cataland et al. · Clinical Nephrology · 2021 · 36 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +14

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, Gema Ariceta, Peter Chen et al. · Blood · 2019 · 25 citations

Life Sciences, Immunology, Internal Medicine +11

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Bradley P. Dixon, David Kavanagh, Alvaro Domingo Madrid Aris et al. · Kidney Medicine · 2024 · 22 citations · Full text

Medicine, Hematology, Pharmacotherapy +14